Bank of America just raised its EUR/USD forecast
Investing.com - Natera (NASDAQ:NTRA) shares rose after UBS reiterated its Buy rating and $218.00 price target following positive clinical trial results for the company’s Signatera test. Currently trading at $161.94, the stock has shown strong momentum with a 30% return over the past year. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $37 to $255.
The company announced positive topline results from the Roche/Genentech-sponsored Phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC) and is finalizing its premarket approval application to the FDA as a companion diagnostic test. With impressive revenue growth of 44% year-over-year and an "GREAT" overall financial health score from InvestingPro, Natera appears well-positioned to capitalize on this opportunity.
UBS views this announcement as positive for Natera as it builds clinical evidence supporting Signatera’s predictive value in cancer treatment outcomes.
While muscle-invasive bladder cancer represents a relatively small market with approximately 21,000 new cancer cases annually, and Tecentriq is not widely used for this indication according to physician feedback, the potential FDA approval could provide significant advantages.
An FDA label could differentiate Signatera from competing minimal residual disease tests, potentially boost adoption beyond bladder cancer, and strengthen reimbursement cases following regulatory approval and inclusion in treatment guidelines, contributing to increasing average selling prices for the test.
In other recent news, Natera Inc . reported its second-quarter 2025 earnings with a significant revenue beat, posting $546.6 million, which exceeded forecasts by 14.85%. However, the company’s earnings per share (EPS) fell short, coming in at -$0.74 compared to the expected -$0.62. Additionally, Natera’s Signatera blood test showed positive results in a phase III clinical trial for muscle-invasive bladder cancer, demonstrating improved survival rates for patients. Following these developments, several analyst firms adjusted their price targets for Natera. RBC Capital raised its price target to $255, citing a strong performance across all categories. Bernstein SocGen increased its target to $205, noting the company’s strong revenue figures. TD Cowen also adjusted its target to $215, highlighting Natera’s robust quarterly performance. These recent developments reflect the company’s ongoing momentum in both clinical and financial arenas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.